TY - JOUR
T1 - Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer
AU - Von Felden, Johann
AU - Garcia-Lezana, Teresa
AU - Dogra, Navneet
AU - Gonzalez-Kozlova, Edgar
AU - Ahsen, Mehmet Eren
AU - Craig, Amanda
AU - Gifford, Stacey
AU - Wunsch, Benjamin
AU - Smith, Joshua T.
AU - Kim, Sungcheol
AU - Diaz, Jennifer E.L.
AU - Chen, Xintong
AU - Labgaa, Ismail
AU - Haber, Philipp
AU - Olsen, Reena
AU - Han, Dan
AU - Restrepo, Paula
AU - D'Avola, Delia
AU - Hernandez-Meza, Gabriela
AU - Allette, Kimaada
AU - Sebra, Robert
AU - Saberi, Behnam
AU - Tabrizian, Parissa
AU - Asgharpour, Amon
AU - Dieterich, Douglas
AU - Llovet, Josep M.
AU - Cordon-Cardo, Carlos
AU - Tewari, Ash
AU - Schwartz, Myron
AU - Stolovitzky, Gustavo
AU - Losic, Bojan
AU - Villanueva, Augusto
N1 - Funding Information:
Competing interests JvF, BL and AV are inventors in a provisional patent application for the 3-smRC signature. JvF received advisory board fees from Roche. DD’A received consulting fees from Almylam and Novartis. JML is receiving research support from Bayer HealthCare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb, Boehringer-Ingelheim and Ipsen, and consulting fees from Eli Lilly, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Eisai Inc, Celsion Corporation, Exelixis, Merck, Ipsen, Genentech, Roche, Glycotest, Nucleix, Sirtex, Mina Alpha Ltd and AstraZeneca. AV has received consulting fees from Boehringer Ingelheim, Guidepoint and Fujifilm; advisory board fees from Bristol-Myers Squibb, Genentech, Gilead, Nucleix and NGM Pharmaceuticals; and research support from Eisai Pharmaceuticals. The remaining authors have nothing to declare in relation to this manuscript.
Funding Information:
Funding JvF is supported by the German Research Foundation (grant numbers: FE1746/1-1 and FE1746/3-1) and the Clinician Scientist Programme at University Medical Centre Hamburg. TG-L is supported by the Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociación Española para el Estudio del Hígado, AEEH). AC is supported by the National Cancer Institute, Ruth L Kirschstein NRSA Institutional Research Training (grant number: CA078207). MEA, JELD, XC and BL were supported by the Icahn Institute of Genomics and Multiscale Biology. IL is supported by a grant from the Swiss National Science Foundation, from Foundation Roberto and Gianna Gonella and Foundation SICPA. PH is supported by the German Research Foundation (gran number: HA8754/1-1). DD’A is supported by the Grant for Studies Broadening from the Spanish Association for the Study of the Liver (AEEH) and the Cancer Research Grant from Nuovo Soldati Foundation. JML is supported by grants from the US Department of Defence (grant number: CA150272P3), European Commission Framework Programme 7 (HEPTROMIC, proposal number: 259744) and Horizon 2020 Programme (HEPCAR, proposal number: 6 67 273–2), the Asociación Española Contra el Cáncer (AECC), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2013-41027) and Grup de Recerca Consolidat–Recerca Translacional en Oncologia Hepàtica, AGAUR (Generalitat de Catalunya), SGR 1162. CC-C is supported by NCI (grant number: P01-CA087497) and NIH (grant number: U54-OD020353). AV is supported by the US Department of Defence (grant number: CA150272P3).
Publisher Copyright:
©
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Objective Surveillance tools for early cancer detection are suboptimal, including hepatocellular carcinoma (HCC), and biomarkers are urgently needed. Extracellular vesicles (EVs) have gained increasing scientific interest due to their involvement in tumour initiation and metastasis; however, most extracellular RNA (exRNA) blood-based biomarker studies are limited to annotated genomic regions. Design EVs were isolated with differential ultracentrifugation and integrated nanoscale deterministic lateral displacement arrays (nanoDLD) and quality assessed by electron microscopy, immunoblotting, nanoparticle tracking and deconvolution analysis. Genome-wide sequencing of the largely unexplored small exRNA landscape, including unannotated transcripts, identified and reproducibly quantified small RNA clusters (smRCs). Their key genomic features were delineated across biospecimens and EV isolation techniques in prostate cancer and HCC. Three independent exRNA cancer datasets with a total of 479 samples from 375 patients, including longitudinal samples, were used for this study. Results ExRNA smRCs were dominated by uncharacterised, unannotated small RNA with a consensus sequence of 20 nt. An unannotated 3-smRC signature was significantly overexpressed in plasma exRNA of patients with HCC (p<0.01, n=157). An independent validation in a phase 2 biomarker case-control study revealed 86% sensitivity and 91% specificity for the detection of early HCC from controls at risk (n=209) (area under the receiver operating curve (AUC): 0.87). The 3-smRC signature was independent of alpha-fetoprotein (p<0.0001) and a composite model yielded an increased AUC of 0.93. Conclusion These findings directly lead to the prospect of a minimally invasive, blood-only, operator-independent clinical tool for HCC surveillance, thus highlighting the potential of unannotated smRCs for biomarker research in cancer.
AB - Objective Surveillance tools for early cancer detection are suboptimal, including hepatocellular carcinoma (HCC), and biomarkers are urgently needed. Extracellular vesicles (EVs) have gained increasing scientific interest due to their involvement in tumour initiation and metastasis; however, most extracellular RNA (exRNA) blood-based biomarker studies are limited to annotated genomic regions. Design EVs were isolated with differential ultracentrifugation and integrated nanoscale deterministic lateral displacement arrays (nanoDLD) and quality assessed by electron microscopy, immunoblotting, nanoparticle tracking and deconvolution analysis. Genome-wide sequencing of the largely unexplored small exRNA landscape, including unannotated transcripts, identified and reproducibly quantified small RNA clusters (smRCs). Their key genomic features were delineated across biospecimens and EV isolation techniques in prostate cancer and HCC. Three independent exRNA cancer datasets with a total of 479 samples from 375 patients, including longitudinal samples, were used for this study. Results ExRNA smRCs were dominated by uncharacterised, unannotated small RNA with a consensus sequence of 20 nt. An unannotated 3-smRC signature was significantly overexpressed in plasma exRNA of patients with HCC (p<0.01, n=157). An independent validation in a phase 2 biomarker case-control study revealed 86% sensitivity and 91% specificity for the detection of early HCC from controls at risk (n=209) (area under the receiver operating curve (AUC): 0.87). The 3-smRC signature was independent of alpha-fetoprotein (p<0.0001) and a composite model yielded an increased AUC of 0.93. Conclusion These findings directly lead to the prospect of a minimally invasive, blood-only, operator-independent clinical tool for HCC surveillance, thus highlighting the potential of unannotated smRCs for biomarker research in cancer.
KW - cancer prevention
KW - gene expression
KW - hepatobiliary cancer
KW - surveillance
KW - tumour markers
UR - http://www.scopus.com/inward/record.url?scp=85111439315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111439315&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2021-325036
DO - 10.1136/gutjnl-2021-325036
M3 - Article
C2 - 34321221
AN - SCOPUS:85111439315
SN - 0017-5749
VL - 71
SP - 2069
EP - 2080
JO - Gut
JF - Gut
IS - 10
ER -